The global nanoparticle formulation market is expected to reach USD 5.1 billion in 2023 anticipated to grow at a CAGR of 9.4% during the forecast period 2023-2035.

Over time, nanoparticles have evolved into a versatile avenue for precise drug delivery, offering targeted treatment for a spectrum of diseases. Their unique attributes, including their minute size, adaptable surface properties, and multifunctional behavior, distinguish them from conventional drug delivery systems. These advancements in nanoparticle technology present a myriad of benefits, encompassing heightened treatment specificity, improved stability, increased solubility in water, and prolonged retention within the body. Furthermore, these innovative nanoparticles not only revolutionize drug delivery but also wield considerable influence across diverse healthcare domains, spanning diagnostic assays, dentistry, tissue engineering, and medical imaging.

However, the development and formulation of nanoparticles represents a complex and financially demanding endeavor. The process involves intricate engineering employing advanced techniques that necessitate specialized technical expertise. Consequently, researchers and drug developers are increasingly turning to specialized contract service providers equipped with the requisite knowledge and technological prowess to engineer and formulate these nanoparticles. With the escalating demand for nanoparticle-based therapies, the market for nanoparticle formulation is poised for significant expansion in the foreseeable future.

Report Coverage

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of nanoparticle formulation technologies and services market and its likely evolution in the mid-term and long term.
  • An overview of the nanoparticles, highlighting the different types of nanoparticles and methods of nanoparticle formulation. It also features the various applications of nanoparticle-based systems in the biotechnology and pharmaceutical industry. Further, it discusses the various challenges associated with formulation of nanoparticles, as well as the growing need for outsourcing the formulation of such products.
  • Detailed assessment of the current technology landscape of nanoparticle formulation technologies, based on several relevant parameters, such as type of nanoparticle(s) formulated, type of molecule(s) delivered, therapeutic area(s), compatible dosage form(s) and route(s) of administration.
  • Technology competitiveness analysis of nanoparticle formulation technologies based on developer power (in terms of the experience of the developer), technology strength (in terms of type of nanoparticle(s) formulated, formulation method(s) used, type of molecule(s) delivered, compatible dosage form(s), compatible drug release mechanism, compatible for long-acting drug delivery and route(s) of administration) and technology applicability (in terms of therapeutic area(s)).
  • Detailed competitiveness analysis of nanoparticle formulation service providers based on company strength (in terms of years of experience and company size) and service strength.
  • Detailed profiles of prominent players developing technologies and offering services in the nanoparticle formulation domain across North America, Europe and Asia-Pacific.
  • A detailed analysis of the partnerships inked between stakeholders engaged in this domain, since 2018, covering technology licensing agreements, research and development agreements, product development agreements, manufacturing agreements, mergers and acquisitions, technology integration agreements and other relevant agreements
  • An in-depth analysis of various patents that have been filed / granted related to nanoparticle formulation, since 2018, taking into consideration parameters, such as publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization.
  • An insightful framework evaluating type of nanoparticles based on various parameters, such as number of technologies, number of drugs in clinical trials, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective types of nanoparticles currently adopted by stakeholders.
  • A comprehensive market forecast and opportunity analysis, highlighting the future potential of the nanoparticle formulation services market till 2035. We have segregated the current and upcoming opportunity based on type of nanoparticle (organic nanoparticles (polymeric nanoparticles, lipid nanoparticles, viral nanoparticles, protein-based nanoparticles and other organic nanoparticles), inorganic nanoparticles (metal nanoparticles, quantum dots, silica nanoparticles, magnetic nanoparticles and other inorganic nanoparticles) and carbon-based nanoparticles), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).


Key Market Companies

  • Ascension Sciences
  • DIANT Pharma
  • ExonanoRNA
  • Nanoform
  • NanoVation Therapeutics
  • NanoVelos
  • NTT Biopharma
  • Organoid-X BioTech
  • Vaxinano